Metastatic Breast Cancer Clinical Trials

71 studies are recruiting for metastatic breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

   This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospec…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale Cancer Center Clinical Trials Office, New Haven, Connecticut

   Locations

   6 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07340541 on ClinicalTrials.gov

2. Pulsed Electric Field Ablation for Metastatic Breast Cancer

   This is a phase I trial of the safety of image-guided pulsed electric field (PEF) ablation for the locoregional treatment of superficial soft tissue lesions in adults with metastatic breast cancer using the AliyaTM Pulsed Electric Field System.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT07487844 on ClinicalTrials.gov

3. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

   This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hor…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beverly Hills Cancer Center, Beverly Hills, California

   Locations

   79 in total

   Run by

   BioNTech SE

   See if you can join NCT06827236 on ClinicalTrials.gov

4. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

   This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a sui…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Oncology Institute of Hope and Innovation, Cerritos, California

   Locations

   105 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06324357 on ClinicalTrials.gov

5. A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

   Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06246968 on ClinicalTrials.gov

6. BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

   This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Iowa Hospitals and Clinics, Iowa City, Iowa

   Locations

   14 in total

   Run by

   BeOne Medicines

   See if you can join NCT06756932 on ClinicalTrials.gov

7. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

8. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

   This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven cohorts will be enrolled in parallel in this study: Cohort 1…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope - Duarte, Duarte, California

   Locations

   53 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT03424005 on ClinicalTrials.gov

9. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

   First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   44 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06625775 on ClinicalTrials.gov

10. Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

    Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied na…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    3 in total

    Run by

    Northwestern University

    See if you can join NCT06062498 on ClinicalTrials.gov

11. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary …

    Stage

    Phase 3

    Ages

    60 and older

    Site

    Ironwood Cancer & Research Centers, Chandler, Arizona

    Locations

    73 in total

    Run by

    American Society of Clinical Oncology

    See if you can join NCT06377852 on ClinicalTrials.gov

12. Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

    This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Emory University, Atlanta, Georgia

    Locations

    7 in total

    Run by

    Kathy Miller

    See if you can join NCT05846789 on ClinicalTrials.gov

13. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    231 in total

    Run by

    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

14. PRE-ISPY Phase I/II Oncology Platform Program

    PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama

    Locations

    10 in total

    Run by

    QuantumLeap Healthcare Collaborative

    See if you can join NCT05868226 on ClinicalTrials.gov

15. Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

    This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Diego, San Diego, California

    Locations

    4 in total

    Run by

    University of California, San Francisco

    See if you can join NCT05964504 on ClinicalTrials.gov

16. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix, Arizona

    Locations

    79 in total

    Run by

    BriaCell Therapeutics Corporation

    See if you can join NCT06072612 on ClinicalTrials.gov

17. Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer

    The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07179809 on ClinicalTrials.gov

18. HER-2 B Cell Peptide Vaccine

    This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianpolis, Indiana

    Run by

    Pravin T.P Kaumaya

    See if you can join NCT06414733 on ClinicalTrials.gov

19. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

    The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama, Birmingham, Alabama

    Locations

    11 in total

    Run by

    Ana C Garrido-Castro, MD

    See if you can join NCT06533826 on ClinicalTrials.gov

20. PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

    The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Kristina A. Fanucci

    See if you can join NCT07222215 on ClinicalTrials.gov

21. A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

    The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBio…

    Stage

    Not phased

    Ages

    22 and older

    Site

    Karmanos Cancer Institute at McLaren Bay Region, Bay City, Michigan

    Locations

    8 in total

    Run by

    Barbara Ann Karmanos Cancer Institute

    See if you can join NCT07227831 on ClinicalTrials.gov

22. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Banner Health MD Anderson AZ, Gilbert, Arizona

    Locations

    192 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT05894239 on ClinicalTrials.gov

23. Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu

    The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are receiving Enhertu.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

    Run by

    University of Utah

    See if you can join NCT07203378 on ClinicalTrials.gov

24. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Clinical Trial Site, Beverly Hills, California

    Locations

    181 in total

    Run by

    Olema Pharmaceuticals, Inc.

    See if you can join NCT07085767 on ClinicalTrials.gov

25. A Study of HLD-0117 in Patients With Metastatic Breast Cancer

    Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale University School Of Medicine, New Haven, Connecticut

    Locations

    6 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07524855 on ClinicalTrials.gov